Louis W Sullivan sold $9.8M of UTHR
director at UNITED THERAPEUTICS Corp. 26,209 shares at an average of $373.22, traded Dec 18, 2024, filed Dec 19, 2024.
Score components
- +15RoleDirector
- +25Trade size$9.8M at market
- +20Share of holdings soldSold 84% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001562180-24-008520, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 18, 2024 | MOption exercise Common Stock | +15,000 | $175.43 | $2.6M | 31,260 | Dec 19, 2024 |
| Dec 18, 2024 | SOpen-market sale Common Stock | -1,121 | $366.11 | $410k | 30,139 | Dec 19, 2024 |
| Dec 18, 2024 | SOpen-market sale Common Stock | -600 | $366.97 | $220k | 29,539 | Dec 19, 2024 |
| Dec 18, 2024 | SOpen-market sale Common Stock | -1,307 | $368.50 | $482k | 28,232 | Dec 19, 2024 |
| Dec 18, 2024 | SOpen-market sale Common Stock | -2,100 | $369.32 | $776k | 26,132 | Dec 19, 2024 |
| Dec 18, 2024 | SOpen-market sale Common Stock | -1,400 | $370.30 | $518k | 24,732 | Dec 19, 2024 |
| Dec 18, 2024 | SOpen-market sale Common Stock | -1,501 | $373.12 | $560k | 23,231 | Dec 19, 2024 |
| Dec 18, 2024 | SOpen-market sale Common Stock | -200 | $371.25 | $74k | 23,031 | Dec 19, 2024 |
| Dec 18, 2024 | SOpen-market sale Common Stock | -2,451 | $374.14 | $917k | 20,580 | Dec 19, 2024 |
| Dec 18, 2024 | SOpen-market sale Common Stock | -2,200 | $375.00 | $825k | 18,380 | Dec 19, 2024 |
| Dec 18, 2024 | SOpen-market sale Common Stock | -500 | $374.46 | $187k | 17,880 | Dec 19, 2024 |
| Dec 18, 2024 | SOpen-market sale Common Stock | -200 | $379.30 | $76k | 17,680 | Dec 19, 2024 |
| Dec 18, 2024 | SOpen-market sale Common Stock | -700 | $380.12 | $266k | 16,980 | Dec 19, 2024 |
| Dec 18, 2024 | SOpen-market sale Common Stock | -620 | $381.41 | $236k | 16,360 | Dec 19, 2024 |
| Dec 18, 2024 | SOpen-market sale Common Stock | -100 | $382.63 | $38k | 16,260 | Dec 19, 2024 |
| Dec 18, 2024 | SOpen-market sale Common Stock | -752 | $368.67 | $277k | 15,508 | Dec 19, 2024 |
| Dec 18, 2024 | SOpen-market sale Common Stock | -1,926 | $370.02 | $713k | 13,582 | Dec 19, 2024 |
| Dec 18, 2024 | SOpen-market sale Common Stock | -100 | $370.78 | $37k | 13,482 | Dec 19, 2024 |
| Dec 18, 2024 | SOpen-market sale Common Stock | -1,525 | $373.06 | $569k | 11,957 | Dec 19, 2024 |
| Dec 18, 2024 | SOpen-market sale Common Stock | -1,962 | $374.17 | $734k | 9,995 | Dec 19, 2024 |
| Dec 18, 2024 | SOpen-market sale Common Stock | -2,700 | $375.03 | $1.0M | 7,295 | Dec 19, 2024 |
| Dec 18, 2024 | SOpen-market sale Common Stock | -400 | $377.46 | $151k | 6,895 | Dec 19, 2024 |
| Dec 18, 2024 | SOpen-market sale Common Stock | -944 | $379.67 | $358k | 5,951 | Dec 19, 2024 |
| Dec 18, 2024 | SOpen-market sale Common Stock | -800 | $381.37 | $305k | 5,151 | Dec 19, 2024 |
| Dec 18, 2024 | SOpen-market sale Common Stock | -100 | $382.25 | $38k | 5,051 | Dec 19, 2024 |
| Dec 19, 2024 | GGift Common Stock | -1,851 | $0.00 | $0 | 3,200 | Dec 19, 2024 |
| Dec 18, 2024 | MOption exercise Stock Optionsderivative | -15,000 | $0.00 | $0 | 0 | Dec 19, 2024 |
Related signals
Other insiders at UNITED THERAPEUTICS Corp and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.1M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.2M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.1M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.1M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.2M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.5M 9,500 shares | -3% | |
| 18Weak | UNITED THERAPEUTICS Corp | Paul A Mahon EVP & GENERAL COUNSEL | $4.7M 8,300 shares | -16% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $3.9M 7,580 shares | -2% | |
| 38Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $1.1M 1,920 shares | -1% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $4.5M 9,500 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.